Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind controlled phase 2 dose-finding study of C-21 for the treatment of Idiopathic-pulmonary-fibrosis

Next Previous
Search
Trial Profile

A double-blind controlled phase 2 dose-finding study of C-21 for the treatment of Idiopathic-pulmonary-fibrosis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buloxibutid (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms AIR-2

    • Most Recent Events

    • 07 Dec 2022 According to a Vicore Pharma media release, the company intends to carry out a directed share issue corresponding to approximately 10 million shares in the Company through an accelerated bookbuilding procedure directed to Swedish and international institutional investors, starting immediately. The net proceedings from the Directed issue are planned to be used for preparation in this trial.
    • 14 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top